The Quantellect read.As of Nov 19, 2026, 4 active firms cover Fennec Pharmaceuticals Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $16.00 to $18.00, so the covering firms are broadly aligned. The average target of $17.00 sits 28% above the current $13.33. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $0.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.00
+27.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $13.33 current
Highest Target$18.00
Average Target$17.00
Lowest Target$16.00
Detailed analyst forecasts for FENC
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate FENC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FENC EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.11 – $0.15 · 3 analysts · +1200% YoY
Next period, 3 analysts expect Fennec Pharmaceuticals Inc to earn $0.13 a share (range $0.11 – $0.15), versus $0.01 a year earlier. Full-year consensus is $0.30, growing to $0.99 the year after.
REVENUE · NEXT QUARTER
$22.5M
Range $21.9M – $22.8M · 3 analysts · +49% YoY
Revenue is expected to reach $22.5M (range $21.9M – $22.8M), +48.8% year-over-year. Full-year consensus is $74.6M, rising to $105.4M next year.
Top analysts covering Fennec Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FENC.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
No targeton FENC
Overall win rate
61%
+ Follow
#2
David Nierengarten
Wedbush · Rank #24
Buy
$16.00+20.0% to target
Overall win rate
48%
+ Follow
#3
David Amsellem
Piper Sandler · Rank #124
Buy
$18.00+35.0% to target
Overall win rate
50%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$16.00+20.0% to target
Overall win rate
36%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #567
Buy
$15.00+12.5% to target
Overall win rate
30%
+ Follow
FENC stock forecast FAQ
What is FENC's average 12-month price target?+
The 4 active firms with a live target average $17.00 for Fennec Pharmaceuticals Inc over the next 12 months, ranging from a $18.00 high to a $16.00 low, as of Nov 19, 2026.
Is FENC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FENC?+
The Street-high target is $18.00 (B. Riley Securities), and the Street-low is $16.00 (HC Wainwright & Co.). The average of all 4 active-firm targets is $17.00.
How many active Wall Street firms cover FENC?+
4 active firms have a recognized rating on Fennec Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FENC?+
Among analysts who currently cover FENC, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy.
What is Fennec Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.11 – $0.15) across 3 analysts. Full-year EPS is projected at $0.30, rising to $0.99 the following year.
How much revenue is Fennec Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $22.5M (range $21.9M – $22.8M). Full-year revenue is projected at $74.6M, growing to $105.4M next year.
Have analysts been upgrading or downgrading FENC lately?+
As of Nov 19, 2026, 4 of 4 active firms rate FENC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FENC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.